Phase 3 clinical trials of the vaccine was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the second dose, conducted at 25 sites across India.
Phase 3 clinical trials of the vaccine was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the second dose, conducted at 25 sites across India.